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Abstract
Background: To describe the development of polypharmacy and its components in a British birth cohort in its
seventh decade and to investigate socioeconomic and gender differences independent of disease burden.
Methods: Data from the MRC National Survey for Health and Development were analysed to determine the prevalence
and composition of polypharmacy at age 69 and changes since ages 60 to 64. Multinomial regression was used to test
associations between gender, education and occupational social class and total, cardiological and non-cardiological
polypharmacy controlling for disease burden.
Results: At age 69, 22.8% of individuals were taking more than 5 medications. There was an increase in the use of 5 to 8
medications (+ 2.3%) and over 9 medications (+ 0.8%) between ages 60–64 and 69. The greatest increases were found for
cardiovascular (+ 13.4%) and gastrointestinal medications (+ 7.3%). Men experienced greater cardiological polypharmacy,
women greater non-cardiological polypharmacy. Higher levels of education were associated with lower polypharmacy
independent of disease burden, with strongest effects seen for over five cardiological medications (RRR 0.3, 95% CI 0.2–0.5
p < 0.001 for advanced secondary qualifications compared with no qualification); there was no additional
effect of social class.
Conclusions: Polypharmacy increased over the seventh decade. Those with lower levels of education had
more polypharmacy (total, cardiological and non-cardiological), even allowing for disease burden. Further
analysis of future outcomes resulting from polypharmacy should take into account educational and gender
differences, in an effort to identify at-risk populations who could benefit from medication reviews.
Keywords: Polypharmacy, Education, Social class, Socioeconomic position, Epidemiology, Disease burden,
Cardiology, Cohort, Life course
Background
Polypharmacy is growing in the general population, with
over half of those over age 65 in the UK taking more
than three prescribed medications [1]. Between 1995
and 2010 the proportion of individuals prescribed five or
more medications in a large-scale Scottish cohort study
rose from 11.4 to 20.8% of all adults [2]. As individual
lifespans increase, more chronic diseases accumulate
over time; and a growing catalogue of pharmacological
treatments for these diseases results in higher numbers
of prescriptions [3]. In the MRC National Survey for
Health and Development (NSHD), we previously re-
ported that by their early sixties the majority of men and
women have at least two clinical disorders requiring
monitoring or treatment [4]; and by their late sixties,
one in five have three or more doctor-diagnosed disor-
ders [5]. While an increase in therapeutic options for
chronic disease is welcome, often the complex interplay
between these medicines is less well accounted for. Ad-
verse drug reactions are estimated to account for around
6.5% of all hospital admissions in the UK, the majority
of which are avoidable [6]. The risk of a significant inter-
action between pharmaceutical therapies rises along with
the number of prescribed medications [7]. It is for this
reason that polypharmacy has been linked with
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increased risk of falls, reduced functional status and cog-
nition, and higher all-cause mortality in later life [8–10].
Prior research has identified that female gender [11, 12],
lower socioeconomic position and lower education [13, 14]
increases the risk of polypharmacy. These groups are also
at significantly increased risk of multi-morbidity, the key
driver of polypharmacy [11, 15]. In a large scale analysis of
Scottish primary care health records, those in more
economically deprived areas had an earlier onset of multi-
morbidity, and a higher proportion of chronic obstructive
pulmonary disease (COPD), painful disorders and depres-
sion [16]. Those on treatments for specific disorders, such
as cardiovascular syndromes, are far more likely to be on
multiple therapeutic agents [3, 11], perhaps as a result of
more established evidence bases for the use of multi-drug
treatment regimens in this field. These drugs vary in their
side-effects and risk of interaction with other pharmaceu-
tical agents [17]. Cardiovascular medications in particular
are most commonly associated with adverse drug reactions
in older adults, and this is the most frequently prescribed
British National Formulary (BNF) category of medication
in the general population [2, 18]. Men, and individuals from
lower socioeconomic groups, are more likely to suffer from
cardiovascular disorders [4, 19] and consequently cardio-
vascular polypharmacy [20, 21].
Within studies on its determinants, polypharmacy is
commonly defined by an arbitrary cut-off of greater
than a set number of total medications [22, 23].
Given both the prominence of cardiovascular medica-
tion prescription in older adults, and the increased
side effect profile they carry, it is worth distinguishing
between cardiological and non-cardiological polyphar-
macy and investigating the effects of gender and so-
cioeconomic variation, independent of disease burden,
on composition of polypharmacy. This understanding
of the genesis of cardiovascular polypharmacy might
help us better identify at-risk groups who may benefit
from targeted interventions to reduce potential harm
caused by adverse drug events.
We use the oldest of the British birth cohort studies
to: a) describe medication use, general polypharmacy,
cardiological polypharmacy and non-cardiological poly-
pharmacy at age 69; b) assess the change in medication
use across the seventh decade of life; and c) investigate
how gender, education and adult socioeconomic position
are associated with these types of polypharmacy. We
hypothesised that being more educationally or socioeco-
nomically disadvantaged would be associated with poly-
pharmacy even after taking account of disease burden.
Methods
The MRC National Survey for Health and Development
(NSHD), has followed 5362 individuals (2547 women)
since their birth in England, Scotland & Wales in a
single week of March 1946, so far to age 70 [5, 24].
The most recent data collection was conducted
between 2014 and 2015, when study members were
aged 68–69 years. Prior assessment of study member
responses confirmed the NSHD as representative of
this population at the age 60–64 [25]; since then,
additional losses to follow-up other than death have
remained very low [5]. At 68–69 years, following a
postal questionnaire, study members still alive and
with a known current address in mainland Britain
(n = 2698) were invited to have a home visit at age
69; 2149 (79.7%) visits were completed. Invitations
were not sent to those who had died (n = 995), who
were living abroad (n = 583), who restrict participa-
tion to postal questionnaires (n = 22), had previously
withdrawn from the study (n = 632) or had been lost
to follow-up (n = 432) [5].
Prescribed medications
Information on regularly prescribed medication was
collected by the research nurse at age 69 and at the
previous data collection at age 60–64 [24]. At both
follow-ups, the nurse recorded all regularly prescribed
medications, including ‘as required’ medication that was
regularly used, preferably using written lists provided by
the participant rather than relying on verbal recall.
Medications were coded by brand name and then stan-
dardised to generic pharmaceutical names and grouped
by BNF code and chapter [26]. Drug data within each
BNF chapter were subdivided into subcategories of
pharmaceutical agent based on mode of action, primarily
dictated by BNF chapter subsection; with further sepa-
ration of specific agents that are commonly co-
prescribed, including anti-platelets, bronchodilators, an-
tiepileptic medications, dopaminergic antiparkinsonian
medications, insulin and oral antidiabetic agents. From
these data we derived a total count of medications, and
an indicator of general polypharmacy adapted from pre-
existing thresholds [23], namely 5–8 medications
(polypharmacy) and 9 or more medications (extreme
polypharmacy). We also created a total count of cardio-
logical medications (based on Chapter 2 of the BNF)
and non-cardiological medications (all remaining medi-
cations), and classified these into four categories: no
medications, one medication (monotherapy), 2–4 medi-
cations cardiological/non cardiological polypharmacy) 5
or more medications (extreme cardiological/non-cardio-
logical polypharmacy).
Explanatory variables
Explanatory variables chosen were: gender [11, 12];
highest educational qualifications achieved by age 26
[13], grouped into three categories (none; GCSE or-
dinary secondary level or their equivalents; advanced
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secondary-level or higher); own current or if missing
previous occupation by age 53 [2], based on the
Registrar General’s classification of own occupation
using a dichotomous split between manual (III-M, IV
& V) and non-manual (I, II & III-NM); and disease
burden at age 69 [3, 12, 27]. Disease burden was
defined by two measures. The first was a count of
the number of doctor diagnosed chronic diseases or
disorders over the last 10 years, reported by partici-
pants. The research nurse asked about 19 disorders:
heart failure, angina, myocardial infarction, hyper/
hypotension, stroke, diabetes, transient ischaemic at-
tacks, cancer, chronic lung disease, asthma, osteoarth-
ritis, rheumatoid arthritis, osteoporosis, serious eye
trouble, depression, epilepsy, Parkinson’s disease,
memory problems and kidney disease. On this scale,
we distinguished individuals with 0, 1, 2 or 3 or more
doctor diagnosed diseases. To additionally adjust for
the severity of these diseases, as more severe illness
may warrant more medications for treatment, the
second measure was the participant’s binary yes/no
response to the question “Do you have any long-term
illness, health problem or disability that limits the
activities/work you can do?”
Statistical methods
Participant characteristics were described in terms of
the distribution of explanatory variables, medication
use at age 69, and the change in medication use from
age 60–64. Multinomial regression models were used
to investigate the relationships between the explana-
tory variables and extreme total polypharmacy, total
polypharmacy, those taking fewer medications, and
those taking no medication, with the latter as the
reference group. The models were adjusted first for
gender, then additionally for educational qualifications
and adult social class (model one), and finally for
disease burden (model two) to see whether this
explained any observed socioeconomic differences.
We repeated these models for cardiological and non-
cardiological polypharmacy. All statistical analysis was
conducted using Stata 14 (StataCorp, Texas).
Table 1 Characteristics of 2122 MRC NSHD participants with
medication data at age 69
Descriptive statistics Age 69
Sample Size 2122
Female Gender 1084 (51.1%)
Education Status 2011
None 627 (31.2%)
Vocational / O-Level 569 (28.3%)
A-Level / Higher 815 (40.5%)
Social Class 2108
Manual Social Class 589 (27.9%)
Non-Manual Social Class 1519 (72.1%)








No limiting conditions 1554 (73.3%)
Presence of a limiting condition 566 (26.7%)
Medication Data Age 69 Percentage
Changea
Medication Use From Specific BNF Chapter
(1) Gastrointestinal 519 (24.5%) + 7.3%
(2) Cardiovascular 1171 (55.2%) + 13.4%
(3) Respiratory 268 (12.6%) + 1.3%
(4) Central Nervous System 460 (21.7%) + 1.6%
(5) Anti-Infective Agents 53 (2.5%) -0.8%
(6) Endocrine 453 (21.4%) + 3.2%
(7) Obs, Gynae & Urinary 148 (7.0%) + 2.8%
(8) Malignancy & Immune 44 (2.1%) + 1.0%
(9) Nutrition & Blood 241 (11.2%) + 1.3%
(10) Musculoskeletal 194 (9.1%) -3.1%
(11) Ophthalmic 95 (4.5%) + 1.6%
(12) Ear, Nose & Throat 60 (2.8%) - 0.9%
(13) Dermatology 61 (2.9%) - 0.4%
Number of Medications Used
0 430 (20.3%) - 8.6%
1 to 4 1209 (57.0%) + 5.5%
5 to 8 (Polypharmacy) 384 (18.1%) + 2.3%
9+ (Excessive Polypharmacy) 99 (4.7%) + 0.8%
Cardiological Polypharmacy
None 951 (44.8%) - 13.4%
1 (Monotherapy) 379 (17.9%) + 4.0%
2 to 4 (Polypharmacy) 684 (32.2%) + 9.2%
5+ (Extreme Polypharmacy) 108 (5.1%) + 0.2%
Table 1 Characteristics of 2122 MRC NSHD participants with
medication data at age 69 (Continued)
Descriptive statistics Age 69
Non-Cardiological Polypharmacy
None 802 (37.8%) - 4.5%
1 (Monotherapy) 505 (23.8%) + 0.6%
2 to 4 (Polypharmacy) 643 (30.3%) + 2.7%
5+ (Extreme Polypharmacy) 172 (8.1%) + 1.2%
a Percentage change between overall prevalence of medication category
between data collections at age 60–64 and 69, using same sample of
2001 individuals with data at both time points
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Results
There were 2122 (98.7% of participants, of whom 51%
were female) with known medication data at age 69
(Table 1). Almost a third (31.2%) had no educational
qualifications although almost three quarters had been
in non-manual occupations. A fifth (20%) reported
three or more doctor diagnosed diseases and another
fifth (20.3%) reported two.
Medication use at age 69
At age 69, 79.7% were taking one or more medications;
the maximum number taken was 16 and the median
number was 2 (Fig. 1). Over half (55.2%) were taking
medications for cardiovascular disorders (Table 1). The
other common BNF categories of medication were for:
gastrointestinal disorders (mainly gastro-oesophageal
reflux disease and laxatives) taken by 24.5%; disorders of
the central nervous system (mainly analgesics and anti-
depressants) taken by 21.7%; and endocrine disorders
(mainly diabetes and hypothyroidism) taken by 21.3%.
One in 20 (4.7%) were taking 9 or more medications and
a fifth (18.1%) were taking between 5 and 8.
For most BNF categories, users were prescribed a
single medication only. However for cardiological
polypharmacy, the use of multiple co-existing agents
was common. A single agent was used by less than a
fifth (17.9%) of individuals, a third (32.2%) were on
two to four, and one in twenty (5.1%) was prescribed
over five cardiological medications. When accounting
only for all non-cardiological medications collectively,
a single medication was taken by 37.8% of the
sample, two to four medications by 23.8% and over
five medications by 8.1% (Fig. 1).
Change in medication use since age 60–64
Of the 2122, 1981 (93.3%) participants also had medica-
tion data at ages 60–64. Total medication use increased
with age for the majority of participants. Fewer indivi-
duals remained free from any medication use, falling
from 29.2% at ages 60–64 to 20.6% at age 69. Likewise,
the number of medications taken by each individual also
increased. The greatest proportional increase was among
those taking between 1 and 4 medications (+ 5.5%),
though there was also an increase in numbers of indivi-
duals taking 5 to 8 medications (+ 2.3%) and over 9
medications (+ 0.8%) (Table 1). Cardiological polyphar-
macy also increased, with the proportion of individuals
on two to four cardiological medications showing the
largest increase, rising by almost one in ten (9.2%).
Alongside this increase in the number of medications,
the composition of medication types taken also altered
among the study population. There were increases in
medication use from most BNF chapter groups, with the
greatest increases in the proportion of cardiovascular
(+ 13.4%) and gastrointestinal (+ 7.3%) medications. A
few medication subgroups decreased by a small
proportion with advancing age, for example musculo-
skeletal medication (− 3.1%), largely due to a reduc-
tion in non-steroidal anti-inflammatory prescriptions.
Variation in polypharmacy by gender, socioeconomic
factors and disease burden
Of the 2122 participants with valid medication data,
2001 (94.3%) also had data available for educational at-
tainment by age 26, social class by age 53, total number
of chronic diseases at age 69, and the presence of
functional limitation due to disease.
Fig. 1 Composition of medications at age 69
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Table 2 Relative Risk Ratios for total polypharmacy by gender, socioeconomic factors and disease burden














No Medication (reference) (reference) (reference)
No Polypharmacy (1–4 Meds)
Gender
Male (reference) 0.870 (reference) 0.496 (reference) 0.125
Female 1.0 0.8 1.2 0.9 0.7 1.2 0.8 0.6 1.1
Educational Qualifications by Age 26
None (reference) 0.011 (reference) 0.010 (reference) 0.017
Vocational or O-Level Level 1.0 0.7 1.3 1.0 0.7 1.3 1.0 0.7 1.4
A-Level or Higher 0.7 0.5 0.9 0.7 0.5 0.9 0.7 0.5 0.9
Social Class (age 53)
Manual (reference) 0.624 (reference) 0.592 (reference) 0.498
Non-Manual 0.9 0.7 1.2 1.1 0.8 1.5 1.1 0.8 1.5
Number of Diagnosed Diseases
None (reference) < 0.001 (reference) < 0.001
One 3.2 2.5 4.2 3.1 2.4 4.1
Two 6.9 4.6 10.2 6.5 4.3 9.6
Three or More 9.9 5.7 17.4 8.9 5.1 15.7
Disease Severity
No Limiting Conditions (reference) < 0.001 (reference) < 0.001
Limiting Condition 2.7 1.9 3.9 2.1 1.4 3.0
Polypharmacy (5–8 Meds)
Gender
Male (reference) 0.937 (reference) 0.595 (reference) 0.044
Female 1.0 0.7 1.3 0.9 0.7 1.2 0.7 0.5 1.0
Educational Qualifications by Age 26
None (reference) < 0.001 (reference) < 0.001 (reference) < 0.001
Vocational or O-Level Level 0.8 0.5 1.0 0.7 0.5 1.1 0.7 0.5 1.2
A-Level or Higher 0.3 0.2 0.5 0.4 0.2 0.5 0.3 0.2 0.5
Social Class (age 53)
Manual (reference) 0.001 (reference) 0.290 (reference) 0.853
Non-Manual 0.6 0.4 0.8 0.8 0.6 1.2 1.0 0.6 1.4
Number of Diagnosed Diseases
None (reference) < 0.001 (reference) < 0.001
One 6.6 4.0 10.8 5.8 3.5 9.5
Two 22.0 12.4 39.0 18.1 10.1 32.3
Three or More 93.0 47.4 82.3 67.0 33.8 132.9
Disease Severity
No Limiting Conditions (reference) < 0.001 (reference) < 0.001
Limiting Condition 7.7 5.2 11.4 4.6 3.0 7.0
Extreme Polypharmacy (9 + Meds)
Gender
Male (reference) 0.496 (reference) 0.499 (reference) 0.072
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There were few gender differences in total polyphar-
macy prescription; there were more pronounced diffe-
rences by education, social class, number of diagnosed
diseases and disease severity (Table 2). Not surprisingly,
the number of diagnosed diseases was a major risk for
all types of medication use; as was disease severity. In
gender-adjusted models, higher education was associated
with lower likelihood of any medication, polypharmacy
and extreme polypharmacy. For example the relative risk
ratio (RRR) for extreme polypharmacy was 0.2, 95% con-
fidence intervals (CI) 0.1–0.5 for those with advanced
secondary qualifications, and 0.6 (95% CI 0.3–1.1) for
those with secondary level qualifications compared with
those with no qualifications (p < 0.001). These estimates
and those for polypharmacy and any medications were
partly attenuated on adjusting first for social class and
then disease burden, but an inverse association between
advanced secondary qualifications and total polyphar-
macy remained. The inverse association between non-
manual social class and total polypharmacy was weaker
and more attenuated by education and disease burden.
Cardiological polypharmacy, unlike total polyphar-
macy, varied by gender. Women were less likely to have
cardiological polypharmacy (RRR 0.5, 95% CI 0.4–0.6,
p < 0.001) and extreme cardiological polypharmacy
(RRR 0.3, 95% CI 0.2–0.4, p < 0.001) (Table 3). Higher
levels of education were inversely associated with all
medication use in gender adjusted models, before and
after adjusting for social class and then disease burden.
The estimates for non-manual social class were attenu-
ated by education and by disease burden. Diagnosed
diseases again proved a major driver of cardiological
polypharmacy, though disease severity was not associ-
ated with cardiological polypharmacy in fully adjusted
models.
Patterns for non-cardiological polypharmacy con-
trasted with those for cardiological polypharmacy, with
women having an increased risk of non-cardiological
monotherapy, non-cardiological polypharmacy, and over
double the risk of extreme non-cardiological polyphar-
macy (RRR 2.2 95% CI 1.5–3.3, p < 0.001) (Table 4). The
inverse associations between higher levels of education
and polypharmacy and extreme polypharmacy were
again observed, even in the fully adjusted models, al-
though to a lesser degree than for cardiological poly-
pharmacy. Non-manual social class initially showed an
inverse association in gender adjusted models, but this
was again explained by education. The number of doctor
diagnosed diseases and disease severity remained drivers
of non-cardiological polypharmacy, although the associ-
ation with the number of diagnosed diseases was not as
pronounced as for cardiological medications.
Discussion
At age 69, total polypharmacy was present in over a fifth
of individuals in a nationally representative British cohort,
Table 2 Relative Risk Ratios for total polypharmacy by gender, socioeconomic factors and disease burden (Continued)














No Medication (reference) (reference) (reference)
Female 0.9 0.5 1.3 0.9 0.5 1.4 0.6 0.4 1.0
Educational Qualifications by Age 26
None (reference) < 0.001 (reference) < 0.001 (reference) < 0.001
Vocational or O-Level Level 0.5 0.3 0.8 0.5 0.3 1.0 0.6 0.3 1.1
A-Level or Higher 0.2 0.1 0.4 0.3 0.1 0.5 0.2 0.1 0.5
Social Class (age 53)
Manual (reference) < 0.001 (reference) 0.046 (reference) 0.390
Non-Manual 0.4 0.2 0.6 0.6 0.4 1.0 0.8 0.4 1.4
Number of Diagnosed Diseases
None (reference) < 0.001 (reference) < 0.001
One 2.1 0.6 7.0 1.6 0.5 5.6
Two 19.0 6.5 55.7 13.6 4.5 40.5
Three or More 201.9 70.7 576.7 109.9 37.6 321.1
Disease Severity
No Limiting Conditions (reference) < 0.001 (reference) < 0.001
Limiting Condition 21.8 12.6 38.0 10.6 5.9 19.3
Model One: Gender, Education & Social Class. Model Two: Gender, Education, Social Class, Disease Burden & Severity Risk ratios rounded to a single decimal place
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Table 3 Relative Risk Ratios for cardiological polypharmacy by gender, socioeconomic factors and disease burden














No Medication (reference) (reference) (reference)
Monotherapy (1 Med)
Gender
Male (reference) 0.303 (reference) 0.245 (reference) 0.043
Female 0.9 0.7 1.1 0.9 0.7 1.1 0.8 0.6 1.0
Educational Qualifications by Age 26
None (reference) 0.008 (reference) 0.003 (reference) 0.004
Vocational or O-Level
Level
0.6 0.5 0.9 0.6 0.4 0.8 0.6 0.4 0.8
A-Level or Higher 0.7 0.5 0.9 0.6 0.4 0.8 0.6 0.4 0.8
Social Class (age 53)
Manual (reference) 0.933 (reference) 0.189 (reference) 0.116
Non-Manual 1.0 0.8 1.3 1.2 0.9 1.7 1.3 0.9 1.8
Number of Diagnosed Diseases
None (reference) < 0.001 (reference) < 0.001
One 1.7 1.2 2.3 1.7 1.3 2.4
Two 1.9 1.3 2.8 2.0 1.4 3.0
Three or More 4.9 3.2 7.4 0.9 1.7 5.4 3.5 8.3
Disease Severity
No Limiting Conditions (reference) 0.950 (reference) 0.090
Limiting Condition 1.0 0.7 1.4 0.8 0.6 1.0
Polypharmacy (2–4 Meds)
Gender
Male (reference) < 0.001 (reference) < 0.001 (reference) < 0.001
Female 0.7 0.5 0.8 0.6 0.5 0.8 0.5 0.4 0.6
Educational Qualifications by Age 26
None (reference) < 0.001 (reference) (reference) < 0.001
Vocational or O-Level
Level
0.7 0.5 0.9 0.7 0.5 0.9 < 0.001 0.7 0.5 1.0
A-Level or Higher 0.5 0.4 0.7 0.5 0.4 0.7 0.5 0.4 0.7
Social Class (age 53)
Manual (reference) 0.027 (reference) 0.880 (reference) 0.626
Non-Manual 0.8 0.6 1.0 1.0 0.8 1.3 1.1 0.8 1.4
Number of Diagnosed Diseases
None (reference) < 0.001 (reference) < 0.001
One 7.4 5.0 10.8 7.2 4.9 10.6
Two 13.4 8.8 20.2 13.3 8.8 20.2
Three or More 40.2 25.6 63.2 39.5 24.8 62.3
Disease Severity
No Limiting Conditions (reference) < 0.001 (reference) 0.923
Limiting Condition 1.8 1.5 2.3 1.0 0.8 1.3
Extreme Polypharmacy (5+ Meds)
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and over half of this sample received at least one cardio-
vascular prescription. The prevalence of medication use
increased with age across the seventh decade, with the
greatest increase seen in the volume of cardiovascular
prescriptions, particularly in those prescribed between
two to four cardiological medications. Disease burden was
a major predictor of all types of polypharmacy. Those with
higher education were less likely to be prescribed poly-
pharmacy, even when taking this burden into account,
along with gender and social class. The associations with
education were stronger than those with social class, and
all types of polypharmacy were mediated by level of
education. Gender differences were more varied; no diffe-
rences in total polypharmacy were apparent at age 69, yet
women were less likely than men to have cardiovascular
prescriptions, and more likely to have non-cardiovascular
medications.
The primary strengths of this study are the nature of the
NSHD being representative of the general population, and
having age homogeneity. The measures available allowed
accurate capture of a potentially at-risk group for polyphar-
macy and patterns of sociodemographic and health related
factors and disease burden on pharmaceutical prescriptions
to be estimated. In addition, the longitudinal data allow for
description of change in prescribed medications. One
limitation is that medication data relied on self-reports,
albeit collected by research nurses, and making use of pre-
scription lists. Evidence suggests that our method should
provide robust medication data, as self-reported measures
alone correlate well with pharmacy prescription records;
identifying most regular medications and only occasionally
missing ‘as required’ and non-oral medications, such as
transdermal patches [28]. The accuracy of self-reported
diagnosed disease varies dependent on condition severity
[29], though most major diseases have fairly high accuracy
using this measure. Prior work on NSHD showed self-
reported diabetes diagnoses were comparable with GP
records in 95% of cases [30]. Additionally, capping our
measure at 3+ diseases reduces the potential for variance at
higher levels of disease burden. Similarly, our measure of
disease severity, defined as whether long-term illness limits
activity, is likely to detect most severe diseases within the
sample population – although it may be influenced by par-
ticipant perception of expected function. No data were
available to account for the primary general practitioner’s
(GPs) prescribing habits, which holds significant associa-
tions with major polypharmacy [31]. Given the geograph-
ical spread of study members across England, Scotland and
Table 3 Relative Risk Ratios for cardiological polypharmacy by gender, socioeconomic factors and disease burden (Continued)














No Medication (reference) (reference) (reference)
Gender
Male (reference) < 0.001 (reference) < 0.001 (reference) < 0.001
Female 0.4 0.2 0.6 0.4 0.2 0.6 0.3 0.2 0.4
Educational Qualifications by Age 26
None (reference) < 0.001 (reference) < 0.001 (reference) < 0.001
Vocational or O-Level
Level
0.4 0.2 0.6 0.4 0.2 0.7 0.4 0.2 0.8
A-Level or Higher 0.3 0.2 0.4 0.3 0.2 0.5 0.3 0.2 0.5
Social Class (age 53)
Manual (reference) 0.001 (reference) 0.305 (reference) 0.852
Non-Manual 0.5 0.3 0.7 0.8 0.5 1.3 1.0 0.6 1.6
Number of Diagnosed Diseases
None (reference) < 0.001 (reference) < 0.001
One 3.2 1.1 9.2 3.0 1.0 8.6
Two 13.6 5.0 36.6 11.8 4.3 32.2
Three or More 86.5 33.1 226.3 66.8 25.0 178.5
Disease Severity
No Limiting Conditions (reference) < 0.001 (reference) 0.056
Limiting Condition 4.0 2.6 6.2 1.6 1.0 2.6
Model One: Gender, Education & Social Class. Model Two: Gender, Education, Social Class, Disease Burden & Severity
Risk ratios rounded to a single decimal place
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Table 4 Relative Risk Ratios for non-cardiological polypharmacy by gender, socioeconomic factors and disease burden














No Medication (reference) (reference) (reference)
Monotherapy (1 Med)
Gender
Male (reference) 0.013 (reference) 0.018 (reference) 0.034
Female 1.3 1.1 1.7 1.3 1.1 1.7 1.3 1.0 1.6
Educational Qualifications by Age 26
None (reference) 0.123 (reference) 0.325 (reference) 0.433
Vocational or O-Level
Level
1.0 0.7 1.3 1.0 0.7 1.4 1.0 0.7 1.4
A-Level or Higher 0.8 0.6 1.0 0.8 0.6 1.1 0.9 0.6 1.2
Social Class (age 53)
Manual (reference) 0.056 (reference) 0.201 (reference) 0.302
Non-Manual 0.8 0.6 1.0 0.8 0.6 1.1 0.9 0.6 1.1
Number of Diagnosed Diseases
None (reference) < 0.001 (reference) < 0.001
One 1.6 1.2 2.1 1.5 1.1 2.0
Two 2.4 0.7 3.3 2.2 1.5 3.1
Three or More 2.3 1.6 3.4 2.0 1.3 2.9
Disease Severity
No Limiting Conditions (reference) < 0.001 (reference) < 0.001
Limiting Condition 2.3 1.7 3.1 2.0 1.5 2.7
Polypharmacy (2–4 Meds)
Gender
Male (reference) < 0.001 (reference) < 0.001 (reference) < 0.001
Female 1.7 1.4 2.1 1.7 1.3 2.1 1.6 1.3 2.0
Educational Qualifications by Age 26
None (reference) < 0.001 (reference) 0.001 (reference) 0.005
Vocational or O-Level
Level
0.8 0.6 1.1 0.9 0.6 1.1 0.9 0.6 1.2
A-Level or Higher 0.6 0.5 0.8 0.6 0.5 0.8 0.6 0.5 0.8
Social Class (age 53)
Manual (reference) 0.038 (reference) 0.593 (reference) 0.885
Non-Manual 0.8 0.6 1.0 0.9 0.7 1.2 1.0 0.8 1.4
Number of Diagnosed Diseases
None (reference) < 0.001 (reference) < 0.001
One 2.2 1.6 3.0 2.0 1.5 2.7
Two 3.9 2.8 5.6 3.4 2.4 4.8
Three or More 6.5 4.5 9.3 4.8 3.3 7.0
Disease Severity
No Limiting Conditions (reference) < 0.001 (reference) < 0.001
Limiting Condition 3.9 3.0 5.2 3.0 2.3 4.0
Extreme Polypharmacy (5+ Meds)
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Wales, a high variation in GP prescribing patterns is likely
to exist, but this is unlikely to alter results. Also of note,
data used here were collected at two time points, over 5
years apart. Participants may have taken numerous pre-
scriptions of a shorter duration between these time points.
This is suggested, for example, by the low numbers of anti-
infective prescriptions among the cohort. However, given
that it is more important to understand chronicity of medi-
cation use in polypharmacy, this is unlikely to affect our
findings.
The overall prevalence of polypharmacy within the
study sample correlates well with that of a large scale
health records study in Scotland [2], with similar
proportions of individuals taking over five medications,
and a high prevalence of cardiological medications. The
increase in the number of medications taken by partici-
pants between the ages of 60–64 and 69 supports prior
evidence suggesting that medication use increases with
age [2, 11, 32]; of note here is the considerable increase
in cardiovascular prescriptions revealed by this study.
Epidemiological evidence from a Swedish cohort study
suggested that women were 50% more likely to be medi-
cated at any age, though the prevalence of polypharmacy
(over five medications) was roughly equivalent for both
genders by age seventy [11]. A large increase in male
polypharmacy between the ages of 60 and 69 has pre-
viously been noted in large population databases, and
appears to have been replicated in NSHD [33]. Total
polypharmacy in this study follows this trend; however,
gender appears to play a role in the composition of that
polypharmacy, with men prescribed more cardiovascular
drugs than women, in keeping with prior studies on car-
diological polypharmacy [20, 21], even after additionally
adjusting for disease burden in the current study.
Our findings for multi-morbidity, represented here
by the number of diagnosed diseases, supports prior
evidence that this is the major driver of polypharmacy
[3, 11, 15], although again, this appears to have a
greater impact on the number of cardiovascular
rather than non-cardiovascular medications. Disease
severity however was more strongly associated with
non-cardiological polypharmacy, possibly accounting
for the greater breadth of non-cardiological diseases
in the general population leading to more variation in
their severity; with more severe diseases requiring
more medication to treat. Low levels of education
have previously been highlighted as a predictor of
polypharmacy [13, 32, 34] but only some studies have
Table 4 Relative Risk Ratios for non-cardiological polypharmacy by gender, socioeconomic factors and disease burden (Continued)














No Medication (reference) (reference) (reference)
Gender
Male (reference) < 0.001 (reference) < 0.001 (reference) < 0.001
Female 2.2 1.6 3.1 2.2 1.5 3.1 2.2 1.5 3.3
Educational Qualifications by Age 26
None (reference) < 0.001 (reference) < 0.001 (reference) < 0.001
Vocational or O-Level
Level
0.6 0.4 0.9 0.7 0.4 1.0 0.7 0.4 1.1
A-Level or Higher 0.3 0.2 0.4 0.3 0.2 0.5 0.3 0.2 0.5
Social Class (age 53)
Manual (reference) < 0.001 (reference) 0.102 (reference) 0.791
Non-Manual 0.5 0.3 0.7 0.7 0.5 1.1 0.9 0.6 1.5
Number of Diagnosed Diseases
None (reference) < 0.001 (reference) < 0.001
One 3.0 1.5 6.0 2.4 1.1 4.9
Two 6.6 3.2 13.7 4.6 2.2 9.6
Three or More 29.5 15.0 57.9 15.1 7.5 30.4
Disease Severity
No Limiting Conditions (reference) < 0.001 (reference) < 0.001
Limiting Condition 14.2 9.6 21.0 9.0 6.0 13.6
Model One: Gender, Education & Social Class. Model Two: Gender, Education, Social Class, Disease Burden & Severity
Risk ratios rounded to a single decimal place
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controlled for multi-morbidity [14, 34]. In our study,
these associations persisted even when adjusting for
disease burden, and were found to be more
pronounced for cardiovascular medications than for
non-cardiovascular medications. Cardiovascular disor-
ders are strongly associated with negative health
behaviours, such as smoking and reduced exercise
[35], and these negative health behaviours are in turn
associated with lower levels of education and social
class [36, 37]. The resulting disorders such as myo-
cardial infarction, ischaemic heart disease and heart
failure, commonly warrant multiple pharmacological
agents for treatment [27]; leading to a high volume of
cardiovascular polypharmacy in this group. Yet this
may not entirely explain this phenomenon, as we
found that these associations with education also
existed for non-cardiological polypharmacy, and per-
sisted when adjusting for disease severity.
The reasons for the inverse associations between edu-
cation and polypharmacy are therefore potentially multi-
faceted, and could indicate an additional disparity in
interactions with healthcare services. Individuals with
higher levels of education may be more likely to view
encounters with medical professionals as a shared re-
sponsibility, and to question treatment options [38, 39].
Therefore less educated individuals may accept or be of-
fered pharmacological treatment more readily than those
who have spent time exploring side-effect profiles and
alternative therapies. Indeed, prior analysis of GP data
suggests that more money is spent on prescriptions for
individuals of lower socioeconomic position [40]. Fur-
ther research on consultation practice and prescriptions
would be warranted to explore this trend.
Conclusions
When defining polypharmacy by quantity of drugs alone,
key differences in the composition of the medications in-
volved are neglected. Men and those with lower levels of
education take more cardiovascular drugs, which have a
higher risk of potentially adverse drug-drug interactions,
and may have later life consequences such as increased
mortality or reduced functional outcomes. Future
research on polypharmacy outcomes should aim to
account for variations in both the prevalence and com-
position of polypharmacy by gender and education as
well as disease burden. While further work is required to
unpick these associations, they highlight the potential
for targeted medication reviews in high risk populations.
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